Meeting
2017 ASCO Annual Meeting
Survival outcomes of the NeoALTTO study: Updated results of a randomized multicenter phase III neoadjuvant trial.
Authors
Jens Bodo Huober
University of Ulm, Ulm, Germany
Jens Bodo Huober , Eileen McCormick Holmes , Jose Baselga , Evandro De Azambuja , Michael Untch , Debora Fumagalli , Severine Sarp , Istvan Lang , Ian E. Smith , Frances M. Boyle , Binghe Xu , Christophe Lecocq , Lorena De La Pena , Christian Jackisch , Richard D. Gelber , Martine J. Piccart-Gebhart , Serena Di Cosimo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT00553358
Citation
J Clin Oncol 35, 2017 (suppl; abstr 512)
DOI
10.1200/JCO.2017.35.15_suppl.512
Abstract #
512
Poster Bd #
112
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Association of HER2/CEP17 ratio with pCR after HER2-directed neoadjuvant treatments in the phase III NeoALTTO trial.
First Author: Christian F. Singer
Poster
2018 ASCO Annual Meeting
Intrinsic subtypes of HER2-positive breast cancer and their associations with pathologic complete response (pCR) and outcomes: Findings from NSABP B-41, a randomized neoadjuvant trial.
First Author: Sandra M. Swain
Poster
2015 ASCO Annual Meeting
Total pathologic complete response (tpCR) and event-free survival (EFS) with subcutaneous (SC) or intravenous (IV) trastuzumab in HER2-positive early breast cancer (EBC).
First Author: Christian Jackisch
Poster
2023 ASCO Annual Meeting
Taxane combined with lobaplatin or anthracycline for neoadjuvant treatment of triple-negative breast cancer: A single-center, randomized, controlled, phase-II clinical study.
First Author: Cheng Wang